Market accessCompany release

Inspire Medical Systems investor deck flags new CPT code for Inspire V from 2028

🇺🇸 Inspire Medical Systems, Inc. (INSP) · Mon 02 Nov 2026

The sleep apnea neurostimulation maker's November 2026 presentation covers a Category I CPT code, final 2027 Medicare payments, a growth plan and its full-year 2026 outlook.

Inspire Medical Systems, the US maker of the Inspire neurostimulation system for obstructive sleep apnea, has published an investor presentation dated November 2026. According to the company's summary of the deck, it addresses coding, reimbursement, strategy and guidance.

A central item is a new Category I CPT code for Inspire V, which takes effect on 1 January 2028. The presentation also covers final Medicare reimbursement payments for 2027. The material available to VigiEye does not include the code number, the payment amounts or the detail of how either applies to Inspire V procedures, so those points cannot be reported here.

The deck also sets out a strategic growth plan and the company's outlook for full-year 2026. No outlook figures were available in the material reviewed.

Background in the presentation states that more than 150,000 patients have been treated with the system and that the company's 2025 revenue exceeded $900 million.

What it means for your team

  • Market-access teams in the US should note the 1 January 2028 start date for the Category I CPT code for Inspire V and check the detail in the full deck.
  • The final 2027 Medicare payments are already published in the deck, so reimbursement planning for that year can draw on them, although the figures are not summarised here.
  • Regulatory and quality teams should treat this as company-issued investor material, not a regulatory notice, and verify specifics against official CMS and AMA sources.

Company's press release (SEC filing): Inspire Medical Systems, Inc. ↗

Article written by VigiEye from the official source (Inspire Medical Systems, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →